Garnet L. Anderson

Garnet L. Anderson

Auto-generated profile, based on publicly available information

Garnet L. Anderson

Public Health Sciences Division, Fred Hutchinson Cancer Center , Seattle, WA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2004 in JAMA
Verified
Journal Article
Closed access
PDF file
GAGarnet L Anderson
Garnet L Anderson
MLMarian Limacher
Marian Limacher
AAAnnlouise R Assaf
Annlouise R Assaf
TBTamsen Bassford
Tamsen Bassford
SBShirley A A Beresford
Shirley A A Beresford
WCWomen's Health Initiative Steering Committee
Women's Health Initiative Steering Committee
Research from JAMA — Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy — The Women's Health Initiative Randomized Controlled Trial — ContextDespite decades of use and considerable research, the role of estrogen alone in preventing chronic diseases in postmenopausal women remains uncertain.ObjectiveTo assess the effects on major disease incidence rates of the most commonly used postmenopausal hormone therapy in the United States.Design, Setting, and ParticipantsA randomized, double-blind, placebo-controlled disease prevention trial (the estrogen-alone component of the Women's Health Initiative [WHI]) conducted in 40 US clinical centers beginning in 1993. Enrolled were 10 739 postmenopausal women, aged 50-79 years, with prior hysterectomy, including 23% of minority race/ethnicity.InterventionWomen were randomly assigned to receive either 0.625 mg/d of conjugated equine estrogen (CEE) or placebo.Main Outcome MeasuresThe primary outcome was coronary heart disease (CHD) incidence (nonfatal myocardial infarction or CHD death). Invasive breast cancer incidence was the primary safety outcome. A global index of risks and benefits, including these primary outcomes plus stroke, pulmonary embolism (PE), colorectal cancer, hip fracture, and deaths from other causes, was used for summarizing overall effects.ResultsIn February 2004, after reviewing data through November 30, 2003, the National Institutes of Health (NIH) decided to end the intervention phase of the trial early. Estimated hazard ratios (HRs) (95% confidence intervals [CIs]) for CEE vs placebo for the major clinical outcomes available through February 29, 2004 (average follow-up 6.8 years), were: CHD, 0.91 (0.75-1.12) with 376 cases; breast cancer, 0.77 (0.59-1.01) with 218 cases; stroke, 1.39 (1.10-1.77) with 276 cases; PE, 1.34 (0.87-2.06) with 85 cases; colorectal cancer, 1.08 (0.75-1.55) with 119 cases; and hip fracture, 0.61 (0.41-0.91) with 102 cases. Corresponding results for composite outcomes were: total cardiovascular disease, 1.12 (1.01-1.24); total cancer, 0.93 (0.81-1.07); total fractures, 0.70 (0.63-0.79); total mortality, 1.04 (0.88-1.22), and the global index, 1.01 (0.91-1.12). For the outcomes significantly affected by CEE, there was an absolute excess risk of 12 additional strokes per 10 000 person-years and an absolute risk reduction of 6 fewer hip fractures per 10 000 person-years. The estimated excess risk for all monitored events in the global index was a nonsignificant 2 events per 10 000 person-years.ConclusionsThe use of CEE increases the risk of stroke, decreases the risk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years. A possible reduction in breast cancer risk requires further investigation. The burden of incident disease events was equivalent in the CEE and placebo groups, indicating no overall benefit. Thus, CEE should not be recommended for chronic disease prevention in postmenopausal women.

1 February 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KMKristin A. Miller
Kristin A. Miller
DSDavid S. Siscovick
David S. Siscovick
LSLianne Sheppard
Lianne Sheppard
KSKristen Shepherd
Kristen Shepherd
JSJeffrey H. Sullivan
Jeffrey H. Sullivan
JKJoel Kaufman
Joel Kaufman
Fine particulate air pollution has been linked to cardiovascular disease, but previous studies have assessed only mortality and differences in exposure between cities. We examined the association of long-term exposure to particulate matter of less than 2.5 μm in aerodynamic diameter (PM2.5) with cardiovascular events.

1 April 2003 in Nature Reviews Cancer
Verified
Journal Article
Closed access
RERuth Etzioni
Ruth Etzioni
NUNicole Urban
Nicole Urban
SRScott Ramsey
Scott Ramsey
MMMartin McIntosh
Martin McIntosh
SSStephen Schwartz
Stephen Schwartz
LHLeland Hartwell
Leland Hartwell

1 October 2003 in Annals of Epidemiology
Verified
Journal Article
Closed access
JHJennifer Hays
Jennifer Hays
JHJulie R Hunt
Julie R Hunt
FHF.Allan Hubbell
F.Allan Hubbell
GAGarnet L Anderson
Garnet L Anderson
MLMarian Limacher
Marian Limacher
JRJacques E Rossouw
Jacques E Rossouw

1 October 2003 in Annals of Epidemiology
Verified
Journal Article
Closed access
GAGarnet L Anderson
Garnet L Anderson
JMJoann Manson
Joann Manson
RWRobert Wallace
Robert Wallace
BLBernedine Lund
Bernedine Lund
DHDallas Hall
Dallas Hall
RPRoss L Prentice
Ross L Prentice

1 August 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MNMarian L Neuhouser
Marian L Neuhouser
AAAaron K. Aragaki
Aaron K. Aragaki
RPRoss L. Prentice
Ross L. Prentice
JMJoAnn E. Manson
JoAnn E. Manson
RCRowan Chlebowski
Rowan Chlebowski
GAGarnet L. Anderson
Garnet L. Anderson
Obesity is a major public health problem in the United States. Recent data demonstrate that the age-adjusted obesity (body mass index [BMI], calculated as weight in kilograms divided by height in meters squared, ≥30.0) prevalence is 34.9% among all adults 20 years or older while that for overweight plus obesity (BMI ≥ 25.0) is 68.5%.1 Obesity has been associated with breast cancer risk in observational studies,2,3 systematic reviews, and meta-analyses.3-5 More recently, the 2012 Annual Report to the Nation on Cancer6 concluded that overweight and obese women have a relative risk for postmenopausal breast cancer of 1.13 and 1.25, respectively, vs women of normal weight.